← Leaderboards
John F Warner
Juvaris Biotherapeutics, Inc.
$1,033,759
Attributed
$1,033,759
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $385K · FY2006–09$500K$375K$250K$125K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$1,033,759 · 4
By mechanism
R43$536,613 · 1
P51$497,146 · 3
Top collaborators
No co-investigators on record.
Most similar at Juvaris Biotherapeutics, Inc.
Same institution · by research overlap
- Jeff C Fairman$12,403,334
Others in their field
Top investigators on “Macaca”
- Barton F Haynes · Duke University$291,402,363
- Peter Gordon Gillespie · Oregon Health And Science University$96,229,141
- Richard A Gibbs · Baylor College Of Medicine$82,807,896
- Dennis R. Burton · Scripps Research Institute$75,153,374
- Larry S. Schlesinger · Texas Biomedical Research Institute$72,536,876
- Dan H. Barouch · Fred Hutchinson Cancer Center$68,546,715
Research focus
MacacaInfantInstitutionImmunogenicityResourcesFundingUnited States National Institutes Of HealthResearch PersonnelSourceVaccine EfficacyComputer Retrieval Of Information On Scientific Projects DatabaseSiv VaccinesGrantProtocols, TreatmentFormulations, DrugEffectivenessBlindedDendritic Cell ActivationCytokineBaseAntibodiesImmunizationImmunity, CellularImmune Response
Grant awards (5)
VACCINE EFFICACY OF VSV-SIV/MVA-SIV IN INFANT MACAQUES$146,580
P51 · FY2009 · RR · contact PI
VACCINE EFFICACY OF VSV-SIV/MVA-SIV IN INFANT MACAQUES$168,995
P51 · FY2008 · RR · contact PI
VACCINE EFFICACY OF VSV-SIV/MVA-SIV IN INFANT MACAQUES$181,571
P51 · FY2007 · RR · contact PI
Novel Immunostimulant/Adjuvant for HIV Vaccines: Non-Human Primate Studies$151,584
R43 · FY2007 · AI · contact PI
Novel Immunostimulant/Adjuvant for HIV Vaccines: Non-Human Primate Studies$385,029
R43 · FY2006 · AI · contact PI